Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Amneal Pharmaceuticals, Inc. (AMRX) Healthcare & Pipeline Overview

Amneal Pharmaceuticals, Inc. stands out in the healthcare sector as a robust player in the generic and specialty pharmaceutical markets, leveraging its diverse product offerings and strategic partnerships to address a wide range of therapeutic needs.

What Is the Investment Thesis for AMRX?

The company has a market capitalization of $5.39B and a P/E ratio of 33.91, indicating potential undervaluation relative to its peers. Amneal's focus on complex generics and specialty pharmaceuticals allows it to tap into high-growth therapeutic areas, particularly in neurology and endocrinology. With a gross margin of 38.7% and a profit margin of 4.0%, the company demonstrates solid operational efficiency. Key growth catalysts include the expansion of its product pipeline, particularly in the specialty segment, and increasing demand for generic drugs as healthcare costs rise. However, potential risks include regulatory challenges and competitive pressures from established players in the generic drug market. Overall, Amneal's strategic positioning and operational strengths provide a solid foundation for future growth.

Based on FMP financials and quantitative analysis

AMRX Key Highlights

Market capitalization of $5.39B, reflecting a strong market presence.

• P/E ratio of 33.91, indicating potential value compared to industry peers.
• Gross margin of 38.7%, showcasing efficient cost management.
• Profit margin of 4.0%, demonstrating profitability in a competitive market.
• Free cash flow of $0.17 billion, supporting ongoing investments and operational stability.

Who Are AMRX's Competitors?

AMRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AMRX's Key Strengths?

Strong product portfolio in both generic and specialty pharmaceuticals.

• Robust distribution network across various channels.
• Established reputation in the pharmaceutical industry.

What Are AMRX's Weaknesses?

Limited brand recognition compared to larger pharmaceutical companies.

• Dependence on a few key products for revenue generation.
• Potential vulnerabilities to regulatory changes.

What Could Drive AMRX Stock Higher?

Launch of new specialty products targeting CNS disorders expected in Q4 2026.

• Expansion of AvKARE segment through increased government contracts.
• Continuous development of complex generics to meet market demand.

What Are the Key Risks for AMRX?

Rich valuation — a P/E of 33.91 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Regulatory changes impacting drug approval processes.
• Competitive pressures from larger pharmaceutical companies.
• Supply chain disruptions affecting product availability.

What Are the Growth Opportunities for AMRX?

• Expansion into Specialty Pharmaceuticals: Amneal's Specialty segment is poised for growth, particularly with its products targeting central nervous system disorders and endocrinology. The global market for CNS drugs is expected to reach $150 billion by 2027, driven by increasing prevalence of neurological disorders. Amneal's established product offerings, such as Rytary for Parkinson's disease, position it well to capture this growth.
• Increasing Demand for Generic Drugs: The generic drug market is projected to grow significantly as healthcare costs continue to rise. Amneal's Generics segment, which includes a diverse range of complex formulations, is well-positioned to benefit from this trend. The U.S. generic drug market alone is expected to grow at a CAGR of 7% from 2023 to 2028, providing ample opportunities for revenue expansion.
• International Market Expansion: Amneal has a presence in markets such as India and Ireland, which present significant growth potential. Amneal's existing infrastructure and partnerships in these regions can facilitate further expansion.
• Government Contracts and Partnerships: The AvKARE segment's focus on governmental agencies, including the Department of Defense and Veterans Affairs, offers stable revenue streams. As government spending on healthcare increases, Amneal can leverage its established relationships to secure additional contracts, enhancing its revenue stability.
• Innovation in Drug Development: Amneal's commitment to research and development allows it to explore new therapeutic areas and innovative drug formulations. With a focus on complex generics and specialty products, the company can differentiate itself in a crowded market, potentially leading to higher margins and sustained growth.

What Threats Does AMRX Face?

• Intense competition from established pharmaceutical companies.
• Regulatory challenges and potential changes in healthcare policies.
• Market volatility affecting pricing and reimbursement.

What Are AMRX's Competitive Advantages?

• Diverse product offerings across multiple therapeutic areas.
• Established relationships with governmental agencies for stable revenue.
• Strong operational capabilities in complex drug formulations.
• Global presence with manufacturing facilities in key regions.
• Focus on R&D to drive innovation and product differentiation.

What Does AMRX Do?

Founded in 2002, Amneal Pharmaceuticals, Inc. has established itself as a prominent player in the pharmaceutical industry, focusing on the development, licensing, manufacturing, marketing, and distribution of both generic and specialty pharmaceutical products. Originally known as Atlas Holdings, Inc., the company rebranded in 2018 to better reflect its core mission and expanding capabilities. Amneal operates through three primary segments: Generics, Specialty, and AvKARE. The Generics segment is dedicated to creating a wide array of complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, catering to various therapeutic categories. The Specialty segment focuses on branded pharmaceutical products, particularly in the areas of central nervous system disorders, endocrinology, and parasitic infections, with notable products such as Emverm for treating parasitic infections, Rytary for Parkinson's disease, and Unithroid for hypothyroidism. Additionally, the AvKARE segment supplies pharmaceuticals and medical products primarily to governmental agencies, including the Department of Defense and the Department of Veterans Affairs. Amneal's products are marketed through a robust distribution network that includes wholesalers, hospitals, and pharmacies across the United States, India, Ireland, and other international markets, positioning the company as a versatile and competitive entity in the global pharmaceutical landscape.

What Products and Services Does AMRX Offer?

• Develops and manufactures generic and specialty pharmaceuticals.
• Offers a wide range of dosage forms including oral solids, injectables, and topicals.
• Focuses on therapeutic areas such as central nervous system disorders and endocrinology.
• Provides pharmaceuticals and medical products to governmental agencies.
• Markets products through wholesalers, hospitals, and pharmacies.
• Operates internationally, with a strong presence in the U.S. market.

How Does AMRX Make Money?

• Generates revenue through the sale of generic and specialty pharmaceutical products.
• Operates three segments: Generics, Specialty, and AvKARE.
• Sells products to wholesalers, distributors, hospitals, and pharmacies.
• Engages in government contracts for pharmaceuticals and medical supplies.
• Utilizes a diverse product portfolio to mitigate market risks.

What Industry Does AMRX Operate In?

The drug manufacturing industry, particularly in the specialty and generic segments, is experiencing significant growth driven by increasing healthcare costs and a rising demand for affordable medication. The global generic drug market is projected to grow at a CAGR of approximately 7% over the next five years, fueled by patent expirations and the need for cost-effective treatment options. Amneal Pharmaceuticals, Inc. operates in a competitive landscape alongside peers such as Lantheus Holdings, Inc. (LNTH), Mirum Pharmaceuticals, Inc. (MIRM), and Indivior PLC (INDV), each vying for market share in a rapidly evolving industry. The company's strategic focus on complex generics and specialty pharmaceuticals positions it well to capitalize on these market trends.

Who Are AMRX's Key Customers?

• Wholesalers and distributors of pharmaceuticals.
• Hospitals and healthcare providers.
• Retail and institutional pharmacies.
• Government agencies, including the Department of Defense.
• Direct consumers through pharmacy channels.

Company Profile

Amneal Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Bridgewater, US. The company is led by CEO Chirag K. Patel. AMRX has traded publicly since 2018.

Amneal Pharmaceuticals, Inc. Financial Trajectory

Amneal Pharmaceuticals, Inc. (AMRX) reported $796.2M in revenue for Q2 FY2026, reflecting 10.2% growth compared to the prior quarter. The company recorded net income of $57.7M, with diluted EPS of $0.18. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, AMRX averaged $0.12 in diluted EPS.

How Amneal Pharmaceuticals, Inc. Is Valued

Amneal Pharmaceuticals, Inc. carries a market capitalization of $5.39B, placing it in the mid-cap category. Analyst price targets span from $16.00 to $25.00, with a consensus of $21.25. At the current price of $16.87, that implies approximately 26% upside potential. Relative to its peer group, AMRX's quantitative score of 62/100 is roughly in line with the peer average of 62/100.

Return on assets is 3.5%, showing how much profit it generates from its asset base. AMRX trades at a trailing price-to-earnings ratio of 33.91, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.9%, the inverse of the P/E and a quick read on earnings relative to price.

Amneal Pharmaceuticals, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.30 places it in the grey zone, a middle ground that warrants monitoring.

Amneal Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 27.9% above estimates on average.

Over the past six months, Amneal Pharmaceuticals, Inc. insiders filed 30 SEC Form 4 transactions — 14 sales and 16 purchases. On net that is roughly 25.1M shares acquired (about $9678963.4B) — insiders putting money in tends to read as conviction.

AMRX Financials

AMRX Latest News

AMRX Analyst Consensus

AMRX MoonshotScore

Common Questions About AMRX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources